10-Q: Avidity Biosciences Reports Strong Cash Position and Clinical Trial Progress in Q3 2024

Avidity Biosciences reports a strong cash position of $1.6 billion and advancements in its clinical programs for myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy in its Q3 2024 filing.

Summary

• Avidity Biosciences reported a net loss of $80.4 million for the three months ended September 30, 2024, and a net loss of $220 million for the nine months ended September 30, 2024.
• The company's cash, cash equivalents, and marketable securities totaled $1.6 billion as of September 30, 2024.
• Collaboration revenue was $2.3 million for the three months ended September 30, 2024, and $7.9 million for the nine months ended September 30, 2024.
• Research and development expenses were $77.2 million for the three months ended September 30, 2024, and $208 million for the nine months ended September 30, 2024.
• The company has three programs in clinical development: del-desiran for DM1, del-brax for FSHD, and del-zota for DMD44.
• The Phase 3 HARBOR trial for del-desiran in DM1 is ongoing, with enrollment on track.
• Initial data from the EXPLORE44 trial for del-zota in DMD44 showed a 25% increase in mean dystrophin production and a 37% increase in exon 44 skipping.
• The biomarker cohort in the Phase 1/2 FORTITUDE trial of del-brax for FSHD has been initiated.
• The company expects to complete enrollment in the biomarker cohort for del-brax in the first half of 2025 and initiate the functional cohort in the first half of 2025.
• The company has raised significant capital through public offerings and private placements, including $379.8 million from a private placement in March 2024 and $432.8 million from a public offering in June 2024.
• The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least 12 months from the date of the filing of this Form 10-Q.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong financial backing and clinical progress, but also acknowledges ongoing losses and risks inherent in drug development. The sentiment is cautiously optimistic.

Positives

• The company has a substantial cash balance of $1.6 billion, providing a strong financial foundation.
• Clinical trials for all three lead programs are progressing, with positive initial data reported for del-zota in DMD44.
• The FDA has removed the partial clinical hold on del-desiran, allowing the Phase 3 trial to proceed.
• The company has successfully raised significant capital through public and private offerings.
• The company is expanding its pipeline with new research and development candidates in skeletal muscle and precision cardiology.
• The company is building a global commercial infrastructure in North America and Europe to support anticipated product launches.

Negatives

• The company continues to incur significant net losses, with a net loss of $220 million for the nine months ended September 30, 2024.
• Research and development expenses are substantial and increasing, reflecting the high cost of clinical trials.
• The company has a limited operating history and has not generated any revenue from product sales.
• The company is reliant on external funding through equity offerings, debt financings, or other capital sources.
• The company identified a material weakness in internal control over financial reporting related to segregation of duties over certain information technology general controls.

Risks

• The company's future success is dependent on the successful development and regulatory approval of its product candidates.
• The company may be unable to raise additional funds or enter into collaborations when needed, which could negatively impact its financial condition.
• Clinical trials are costly and time-consuming, and there is no guarantee of success.
• The company faces competition from other biopharmaceutical companies developing therapies for similar diseases.
• The company's internal control over financial reporting has a material weakness, which could lead to misstatements in financial reporting.
• The company is subject to risks associated with the ongoing hostilities outside the United States.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least 12 months from the date of the filing of this Form 10-Q. The company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other arrangements.

Management Comments

• The company is well positioned as it builds an integrated global biopharmaceutical company and continues to deliver on the RNA revolution.
• The company continues to explore the full potential of its AOC platform through collaborations and partnerships, including programs in immunology, cardiology and other select indications outside of muscle.

Industry Context

Avidity Biosciences is operating in the competitive biopharmaceutical industry, focusing on RNA therapeutics. The company's advancements in clinical trials and its strong cash position are notable in the context of the broader industry, where many companies are also pursuing innovative therapies for rare diseases. The company's focus on its proprietary AOC platform and its collaborations with major pharmaceutical companies like Bristol Myers Squibb and Eli Lilly position it as a significant player in the field.

Comparison to Industry Standards

• Avidity's cash position of $1.6 billion is strong compared to many other clinical-stage biopharmaceutical companies, providing a runway for continued development.
• The reported 25% increase in mean dystrophin production and 37% increase in exon 44 skipping in the del-zota trial are promising results, potentially exceeding outcomes from some other exon-skipping therapies in development for DMD.
• The initiation of the biomarker cohort in the FORTITUDE trial for FSHD is a key step, aligning with industry trends of using biomarkers to accelerate drug development.
• The company's collaboration agreements with Bristol Myers Squibb and Eli Lilly are significant, indicating validation of its technology and potential for future revenue streams, similar to other successful biotech partnerships.
• The company's focus on rare diseases aligns with a growing trend in the biopharmaceutical industry, where there is increasing investment and regulatory support for therapies targeting unmet medical needs.

Management Changes

Related Party Transactions

• One of the investors who participated in the private placement met the criteria of a related party as such investor was a principal owner of more than 10% of the voting interest in the Company. The Principal Owner purchased 2,121,213 shares of the Company's common stock for $35.0 million.

Stakeholder Impact

• Shareholders: The company's strong cash position and clinical trial progress are positive for shareholders, but the ongoing losses and risks associated with drug development should be considered.
• Employees: The company's growth and expansion may provide opportunities for employees, but the company's financial performance and the competitive nature of the industry could also create uncertainty.
• Patients: The company's clinical programs offer hope for patients with rare diseases, but the success of these programs is not guaranteed.
• Customers: The company does not currently have any commercial products, so there is no immediate impact on customers.
• Suppliers: The company's increasing research and development activities may lead to increased business for suppliers.
• Creditors: The company's strong cash position reduces the risk for creditors, but the company's ongoing losses should be considered.

Next Steps

• The company will continue to enroll patients in the Phase 3 HARBOR trial for del-desiran.
• The company will continue to enroll patients in the EXPLORE44 trial for del-zota and the EXPLORE44 Open-Label Extension.
• The company will complete enrollment in the biomarker cohort for del-brax in the first half of 2025 and initiate the functional cohort in the first half of 2025.
• The company plans to provide a first look at precision cardiology candidates and share a glimpse into next-generation technology innovations in November 2024.
• The company will continue to advance additional exon-skipping candidates from its DMD franchise.

Key Dates

Keywords

RNA therapeutics, Antibody Oligonucleotide Conjugates, AOC, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, clinical trials, del-desiran, del-brax, del-zota, biopharmaceutical, exon skipping, dystrophin, DUX4, FDA, Orphan Designation, Fast Track Designation, Breakthrough Therapy designation, Rare Pediatric Disease designation, public offering, private placement